Optoelectronical methods for screening of Pralmorelin and it's metabolite in urine samples

摘要

GHRP-2, also known as Pralmorelin, is a synthetic peptide drug. It acts as ghrelin/growth-hormone secretagogue receptor agonist, being the first drug of this class introduced clinically. It's used, in a single dose formulation, as a diagnostic agent for growth hormone deficiency (GHD). Administration of GHRP-2 increases the plasmatic concentration of growth hormone. It was clinically tested for tratment of GHD and pituitary dwarfism. GHRP-2 has performance enhancing potential and is prohibited for athletes in section S2: Peptide Hormones, Growth Factors, Related Substances, And Mimetics of WADA (World Antidoping Agency) Prohibited List. In this work we developed and validated a screening method for GHRP-2 and it's two metabolites from urine on LC-HRMS (liquid chromatography coupled with high resolution mass spectrometry)(Q Exactive Plus from Thermo Scientific) and LC-MS/MS triple quadrupole (liquid chromatography coupled with mass spectrometry) (ABSciex QTrap 5500). The validation parameters evaluated were limit of detection, matrix effects, identification criteria, specificity, carry-over and extraction recovery, the evaluated parameters are in accordance with WADA technical documents, both methods being applicable for doping control application.